G8 screening tool for treatment decision-making in elderly colorectal cancer patients

Marín, J.A.; Soler, G.; Martínez-Villacampa, M.; Vázquez, Silvia; Vivas, C. Santos; Margalef, N. Mulet; Teulé, Alexandre; Salazar, Ramón

doi:10.1093/annonc/mdy151.247

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These screening tools (Table 1), such as the G8 [8,9], may be used to identify patients in need of a more comprehensive geriatric assessment (CGA). In patients ≥ 75, lower G8 score is associated with higher rates of chemotherapy dismissal, dose reduction, and poorer overall survival [11,12] CRASH [13] To CGA-comprehensive geriatric assessment; BMI-body mass index; ECOG-Eastern Cooperative Oncology Group performance; MMHS-mini-mental health status; BP-blood pressure; LDH-lactate dehydrogenase; IADLs-instrumental activities of daily living; PFS-progression-free survival; ORR-objective response rate; OS-overall survival.…”

Section: Geriatric Assessmentmentioning

confidence: 99%

Updates on the Management of Colorectal Cancer in Older Adults

O’Donnell,

Hubbard,

Jin

2024

Cancers

View full text Add to dashboard Cite

Colorectal cancer (CRC) poses a significant global health challenge. Notably, the risk of CRC escalates with age, with the majority of cases occurring in those over the age of 65. Despite recent progress in tailoring treatments for early and advanced CRC, there is a lack of prospective data to guide the management of older patients, who are frequently underrepresented in clinical trials. This article reviews the contemporary landscape of managing older individuals with CRC, highlighting recent advancements and persisting challenges. The role of comprehensive geriatric assessment is explored. Opportunities for treatment escalation/de-escalation, with consideration of the older adult’s fitness level. are reviewed in the neoadjuvant, surgical, adjuvant, and metastatic settings of colon and rectal cancers. Immunotherapy is shown to be an effective treatment option in older adults who have CRC with microsatellite instability. Promising new technologies such as circulating tumor DNA and recent phase III trials adding later-line systemic therapy options are discussed. Clinical recommendations based on the data available are summarized. We conclude that deliberate efforts to include older individuals in future colorectal cancer trials are essential to better guide the management of these patients in this rapidly evolving field.

show abstract